ONCOMED PHARMACEUTICALS, INC. (NASDAQ:OMED) Files An 8-K Entry into a Material Definitive Agreement

ONCOMED PHARMACEUTICALS, INC. (NASDAQ:OMED) Files An 8-K Entry into a Material Definitive Agreement
Item 1.01.

Story continues below


OncoMed Pharmaceuticals Inc Exhibit
EX-2.1 2 d665634dex21.htm EX-2.1 EX-2.1 Exhibit 2.1 EXECUTION VERSION AGREEMENT AND PLAN OF MERGER AND REORGANIZATION among: MEREO BIOPHARMA GROUP PLC,…
To view the full exhibit click here

About ONCOMED PHARMACEUTICALS, INC. (NASDAQ:OMED)

OncoMed Pharmaceuticals, Inc. (OncoMed) is a clinical development-stage biopharmaceutical company. The Company focuses on discovering and developing anti-cancer stem cell (CSC) and immuno-oncology therapeutics. The Company’s product candidates and preclinical programs include Demcizumab (Anti-DLL4, OMP-21M18), Tarextumab (Anti-Notch2/3, OMP-59R5), Vantictumab (anti-Fzd7, OMP-18R5), Ipafricept (Fzd8-Fc, OMP-54F28), Brontictuzumab (Anti-Notch1, OMP-52M51), Anti-DLL4/VEGF Bispecific (OMP-305B83), Anti-RSPO3 (OMP-131R10) and GITRL-Fc. The Company’s Demcizumab is a humanized monoclonal antibody that inhibits Delta-like Ligand 4 (DLL4), in the Notch signaling pathway. Tarextumab is an antibody that binds to both the Notch2 and Notch3 receptors. Ipafricept is the Company’s Wnt pathway modulator. GITRL-Fc is a preclinical product candidate targeting glucocorticoid-induced tumor necrosis factor receptor related protein.

An ad to help with our costs